ADC Therapeutics (ADCT) Invested Capital: 2019-2023
Historic Invested Capital for ADC Therapeutics (ADCT) over the last 5 years, with Sep 2023 value amounting to -$54.2 million.
- ADC Therapeutics' Invested Capital fell 124.10% to -$54.2 million in Q3 2023 from the same period last year, while for Sep 2023 it was -$54.2 million, marking a year-over-year decrease of 124.10%. This contributed to the annual value of $506.3 million for FY2022, which is 17.28% up from last year.
- According to the latest figures from Q3 2023, ADC Therapeutics' Invested Capital is -$54.2 million, which was down 531.19% from -$8.6 million recorded in Q2 2023.
- In the past 5 years, ADC Therapeutics' Invested Capital ranged from a high of $34.9 billion in Q4 2021 and a low of -$14.5 billion during Q4 2022.
- Over the past 3 years, ADC Therapeutics' median Invested Capital value was $193.9 million (recorded in 2021), while the average stood at $5.0 billion.
- As far as peak fluctuations go, ADC Therapeutics' Invested Capital soared by 13,868,681.03% in 2020, and later plummeted by 141.54% in 2022.
- ADC Therapeutics' Invested Capital (Quarterly) stood at $555,032 in 2019, then soared by 13,868,681.03% to $11.1 billion in 2020, then crashed by 98.25% to $34.9 billion in 2021, then crashed by 141.54% to -$14.5 billion in 2022, then crashed by 124.10% to -$54.2 million in 2023.
- Its last three reported values are -$54.2 million in Q3 2023, -$8.6 million for Q2 2023, and $157.7 million during Q1 2023.